Teva files Form 144 noting proposed ordinary-share sales

Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported. The filing lists vested awards scheduled 03/03/2026 and a sale by Richard Francis on 02/17/2026 for 447,678 shares with amount 15324799.05.

Insights

Securities Attorney

Notice of proposed resale activity for ordinary shares; procedural disclosure.

The form lists proposed sales routed through Citigroup Global Markets Inc. and identifies compensation awards vesting on 03/03/2026 (quantities: 67,231, 697,211, 194,104). The document includes a reported sale of 447,678 shares on 02/17/2026 with amount 15324799.05.

These disclosures are procedural notices required for resale; the filing does not state routing mechanics, pricing method, or who receives proceeds beyond the listed broker. Subsequent filings would show execution details if and when sales occur.

Equity Markets Analyst

Compensation-related share vesting and a recent large sale are recorded; market impact not assessed here.

The excerpt shows multiple compensation awards vesting on 03/03/2026 totaling listed share counts and a prior reported sale by Richard Francis of 447,678 shares on 02/17/2026. The broker named is Citigroup Global Markets Inc.

Timing and sale methods are not detailed in the excerpt; actual market impact depends on execution, which is not disclosed in this excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the TEVA Form 144 show about share sales?

The filing lists proposed sales of ordinary shares through Citigroup Global Markets Inc. It also reports a reported sale on 02/17/2026 of 447,678 shares with amount 15324799.05.

Which vested awards are listed in the TEVA Form 144?

The excerpt lists compensation awards vesting on 03/03/2026: a Restricted Share Unit award of 67,231 shares and Performance Share Unit awards of 697,211 and 194,104 shares.

Who is the broker named in the TEVA Form 144?

The broker identified is Citigroup Global Markets Inc with an address at 390 Greenwich Street, New York, NY, shown in the filing excerpt as the executing broker for listed sales.

Does the Form 144 state how proceeds will be used?

The provided excerpt does not describe proceeds usage. It records a sale amount of 15324799.05 for the 02/17/2026 transaction but does not state who receives value or how proceeds are allocated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:34 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001673277
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Francis Richard D
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	PRESIDENT AND CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	442935	14333332.31	1149812898	03/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2023	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			67231	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	PERFORMANCE SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			697211	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	PERFORMANCE SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			194104	03/03/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	02/17/2026	447678	15324799.05

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. SHARES WERE SOLD PURSUANT TO A 10B51 PLAN ESTABLISHED IN NOV 2025.
Date of Notice	03/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)